{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T11:25:36Z","timestamp":1791804336214,"version":"4.3.4"},"reference-count":103,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>\n                    Primary immune thrombocytopenia (ITP) is characterized by the dual pathology of peripheral immune-mediated platelet clearance and restricted platelet production by megakaryocytes. The TPO-MPL axis is a central regulator of platelet homeostasis, and ligand-induced receptor activation is associated with downstream JAK2-STAT, MAPK, and PI3K-AKT signaling. This review summarizes the structural and functional features of TPO and MPL, the major immunopathogenic mechanisms of ITP, and the current clinical use of thrombopoietin receptor agonists (TPO-RAs) in ITP. Recent structural and functional studies suggest that TPO-RAs with distinct binding sites may not engage MPL in fully identical ways and may therefore be associated with differences in receptor conformation, dimer geometry, and downstream signaling output. Within this emerging structural and functional framework, these structural and signaling differences may help explain response heterogeneity and the clinical observation that some patients may still benefit after switching agents. However, direct experimental evidence linking switching outcomes to specific alterations in MPL dimer geometry remains lacking, and the available clinical evidence regarding switching comes mainly from retrospective and observational studies, with additional support from\n                    <jats:italic>post hoc<\/jats:italic>\n                    analyses. Overall, continued investigation of the TPO-MPL pathway and its structural basis may help refine our understanding of ITP pathogenesis, treatment-response heterogeneity, and the clinical observations associated with switching, although the proposed mechanistic links still require direct experimental validation.\n                  <\/jats:p>","DOI":"10.3389\/fmed.2026.1798504","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T04:23:50Z","timestamp":1780892630000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["MPL receptor dimerization and the thrombopoietin pathway in primary immune thrombocytopenia: from molecular mechanisms to targeted therapies"],"prefix":"10.3389","volume":"13","author":[{"given":"Yujue","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Hematology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyan","family":"Liu","sequence":"additional","affiliation":[{"name":"First Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Hu","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqi","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijie","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwei","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/jcm6020016","article-title":"Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP)","volume":"6","author":"Zufferey","year":"2017","journal-title":"J Clin Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.4103\/ajts.AJTS_65_17","article-title":"cross-sectional study on thrombopoietin levels in immune thrombocytopenia and its correlation with platelet count, megakaryocytes, and treatment response","volume":"16","author":"Oberoi","year":"2022","journal-title":"Asian J Transfus Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv."},{"key":"B4","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1182\/hematology.2024000594","article-title":"Insights on treatment of adult ITP: algorithm for management and role of multimodal therapy","volume":"2024","author":"Ghanima","year":"2024","journal-title":"Hematology Am Soc Hematol Educ Program."},{"key":"B5","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American society of hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv."},{"key":"B6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ejim.2022.11.022","article-title":"Current approaches for the diagnosis and management of immune thrombocytopenia","volume":"108","author":"Gafter-Gvili","year":"2023","journal-title":"Eur J Intern Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"101141","DOI":"10.1016\/j.blre.2023.101141","article-title":"The many facets of immune-mediated thrombocytopenia: Principles of immunobiology and immunotherapy","volume":"63","author":"Moulinet","year":"2024","journal-title":"Blood Rev."},{"key":"B8","first-page":"1","article-title":"Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura","volume":"38","author":"Harrington","year":"1951","journal-title":"J Lab Clin Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1056\/NEJMe0707126","article-title":"Immune thrombocytopenic purpura\u2013from agony to agonist","volume":"357","author":"Schwartz","year":"2007","journal-title":"N Engl J Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/j.1538-7836.2004.01052.x","article-title":"Autoimmune thrombocytopenia: flow cytometric determination of platelet-associated autoantibodies against platelet-specific receptors","volume":"3","author":"Tomer","year":"2005","journal-title":"J Thromb Haemost."},{"key":"B11","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/bjh.15404","article-title":"Detection of platelet autoantibodies to identify immune thrombocytopenia: state of the art","volume":"182","author":"Porcelijn","year":"2018","journal-title":"Br J Haematol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.3324\/haematol.2018.211086","article-title":"Glycoprotein V is a relevant immune target in patients with immune thrombocytopenia","volume":"104","author":"Vollenberg","year":"2019","journal-title":"Haematologica."},{"key":"B13","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s40265-018-0927-1","article-title":"Fostamatinib: first global approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs."},{"key":"B14","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3324\/haematol.2020.248385","article-title":"Fc\u03b3RI and Fc\u03b3RIII on splenic macrophages mediate phagocytosis of anti-glycoprotein IIb\/IIIa autoantibody-opsonized platelets in immune thrombocytopenia","volume":"106","author":"Norris","year":"2021","journal-title":"Haematologica."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.1182\/bloodadvances.2022009423","article-title":"Serum from half of patients with immune thrombocytopenia trigger macrophage phagocytosis of platelets","volume":"7","author":"Norris","year":"2023","journal-title":"Blood Adv."},{"key":"B16","doi-asserted-by":"publisher","first-page":"7737","DOI":"10.1038\/ncomms8737","article-title":"Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia","volume":"6","author":"Li","year":"2015","journal-title":"Nat Commun."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.3324\/haematol.2021.279751","article-title":"Antiplatelet antibody predicts platelet desialylation and apoptosis in immune thrombocytopenia","volume":"107","author":"Zheng","year":"2022","journal-title":"Haematologica."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1409461","DOI":"10.3389\/fimmu.2024.1409461","article-title":"The role of platelet desialylation as a biomarker in primary immune thrombocytopenia: mechanisms and therapeutic perspectives","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nm.3770","article-title":"The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling","volume":"21","author":"Grozovsky","year":"2015","journal-title":"Nat Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1182\/bloodadvances.2022007751","article-title":"The interplay between GPIb\/IX antibodies, platelet hepatic sequestration, and TPO levels in patients with chronic ITP","volume":"7","author":"Amini","year":"2023","journal-title":"Blood Adv."},{"key":"B21","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/j.1365-2141.1991.tb04530.x","article-title":"Autoantibodies against platelet glycoprotein Ib\/IX: a frequent finding in autoimmune thrombocytopenic purpura","volume":"79","author":"Kiefel","year":"1991","journal-title":"Br J Haematol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s002770050173","article-title":"Platelet autoantibodies (IgG, IgM, IgA) against glycoproteins IIb\/IIIa and Ib\/IX in patients with thrombocytopenia","volume":"72","author":"Kiefel","year":"1996","journal-title":"Ann Hematol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/j.1600-0609.2011.01718.x","article-title":"Autoantibody-mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP)","volume":"88","author":"Najaoui","year":"2012","journal-title":"Eur J Haematol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e574","DOI":"10.1097\/HS9.0000000000000574","article-title":"Immune thrombocytopenia: recent advances in pathogenesis and treatments","volume":"5","author":"Audia","year":"2021","journal-title":"Hemasphere."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1182\/blood.2022018380","article-title":"The role of CD8+ T-cell clones in immune thrombocytopenia","volume":"141","author":"Malik","year":"2023","journal-title":"Blood."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1083\/jcb.147.6.1299","article-title":"Blood platelets are assembled principally at the ends of proplatelet processes produced by differentiated megakaryocytes","volume":"147","author":"Italiano","year":"1999","journal-title":"J Cell Biol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1046\/j.1538-7836.2003.00331.x","article-title":"The birth of the platelet","volume":"1","author":"Hartwig","year":"2003","journal-title":"J Thromb Haemost."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3348","DOI":"10.1172\/JCI26891","article-title":"The biogenesis of platelets from megakaryocyte proplatelets","volume":"115","author":"Patel","year":"2005","journal-title":"J Clin Invest"},{"key":"B29","doi-asserted-by":"publisher","first-page":"623","DOI":"10.3324\/haematol.2014.115634","article-title":"Immune thrombocytopenia: antiplatelet autoantibodies inhibit proplatelet formation by megakaryocytes and impair platelet production in vitro","volume":"100","author":"Iraqi","year":"2015","journal-title":"Haematologica."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1182\/blood-2003-08-2672","article-title":"Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP","volume":"103","author":"McMillan","year":"2004","journal-title":"Blood."},{"key":"B31","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1182\/blood-2002-05-1475","article-title":"Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro","volume":"102","author":"Chang","year":"2003","journal-title":"Blood."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12185-023-03672-1","article-title":"Reference guide for the diagnosis of adult primary immune thrombocytopenia, 2023 edition","volume":"119","author":"Kashiwagi","year":"2024","journal-title":"Int J Hematol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"4307","DOI":"10.1182\/blood-2010-02-267435","article-title":"Contributions of TRAIL-mediated megakaryocyte apoptosis to impaired megakaryocyte and platelet production in immune thrombocytopenia","volume":"116","author":"Yang","year":"2010","journal-title":"Blood."},{"key":"B34","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1055\/s-0040-1718761","article-title":"Immune thrombocytopenia plasma-derived exosomes impaired megakaryocyte and platelet production through an apoptosis pathway","volume":"121","author":"Miao","year":"2021","journal-title":"Thromb Haemost."},{"key":"B35","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41392-022-01167-9","article-title":"Deciphering transcriptome alterations in bone marrow hematopoiesis at single-cell resolution in immune thrombocytopenia","volume":"7","author":"Liu","year":"2022","journal-title":"Signal Transduct Target Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"102345","DOI":"10.1016\/j.rpth.2024.102345","article-title":"Immune attack on megakaryocytes in immune thrombocytopenia","volume":"8","author":"Petito","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"B37","doi-asserted-by":"publisher","first-page":"4068","DOI":"10.1182\/blood.V87.10.4068.bloodjournal87104068","article-title":"Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction","volume":"87","author":"Emmons","year":"1996","journal-title":"Blood."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.hoc.2009.09.001","article-title":"Thrombopoietin and platelet production in chronic immune thrombocytopenia","volume":"23","author":"Kuter","year":"2009","journal-title":"Hematol Oncol Clin North Am."},{"key":"B39","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.thromres.2018.08.021","article-title":"Anti-c-Mpl antibodies in immune thrombocytopenia suppress thrombopoiesis and decrease response to rhTPO","volume":"170","author":"Jing","year":"2018","journal-title":"Thromb Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/369533a0","article-title":"Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand","volume":"369","author":"de Sauvage","year":"1994","journal-title":"Nature."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/0092-8674(94)90450-2","article-title":"Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl","volume":"77","author":"Bartley","year":"1994","journal-title":"Cell."},{"key":"B42","doi-asserted-by":"publisher","first-page":"13023","DOI":"10.1073\/pnas.91.26.13023","article-title":"Human thrombopoietin: gene structure, cDNA sequence, expression, and chromosomal localization","volume":"91","author":"Foster","year":"1994","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B43","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1182\/blood.V98.12.3241","article-title":"Thrombocytopenia caused by the development of antibodies to thrombopoietin","volume":"98","author":"Li","year":"2001","journal-title":"Blood."},{"key":"B44","doi-asserted-by":"publisher","first-page":"14849","DOI":"10.1021\/bi961075b","article-title":"Peptide, disulfide, and glycosylation mapping of recombinant human thrombopoietin from ser1 to Arg246","volume":"35","author":"Hoffman","year":"1996","journal-title":"Biochemistry."},{"key":"B45","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3390\/biom14040489","article-title":"Thrombopoietin, the Primary Regulator of Platelet Production: From Mythos to Logos, a Thirty-Year Journey","volume":"14","author":"Kaushansky","year":"2024","journal-title":"Biomolecules"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1182\/blood.V89.6.1896","article-title":"Human platelets display high-affinity receptors for thrombopoietin","volume":"89","author":"Broudy","year":"1997","journal-title":"Blood."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1073\/pnas.0308530100","article-title":"Structure of the receptor-binding domain of human thrombopoietin determined by complexation with a neutralizing antibody fragment","volume":"101","author":"Feese","year":"2004","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/s41467-024-45356-2","article-title":"Cryo-EM structure of the extracellular domain of murine Thrombopoietin receptor in complex with Thrombopoietin","volume":"15","author":"Sarson-Lawrence","year":"2024","journal-title":"Nat Commun."},{"key":"B49","doi-asserted-by":"publisher","first-page":"101257","DOI":"10.1016\/j.blre.2025.101257","article-title":"Application of thrombopoietic agents in cancer therapy-induced thrombocytopenia: a comprehensive review","volume":"70","author":"Mei","year":"2025","journal-title":"Blood Rev."},{"key":"B50","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1172\/JCI26674","article-title":"The molecular mechanisms that control thrombopoiesis","volume":"115","author":"Kaushansky","year":"2005","journal-title":"J Clin Invest."},{"key":"B51","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1182\/blood.V87.6.2154.bloodjournal8762154","article-title":"Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets","volume":"87","author":"Fielder","year":"1996","journal-title":"Blood."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s40265-021-01553-7","article-title":"Thrombopoietin receptor agonists (TPO-RAs): drug class considerations for pharmacists","volume":"81","author":"Gilreath","year":"2021","journal-title":"Drugs."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1182\/blood-2015-01-569129","article-title":"Regulating billions of blood platelets: glycans and beyond","volume":"126","author":"Grozovsky","year":"2015","journal-title":"Blood."},{"key":"B54","first-page":"282","article-title":"Managing thrombocytopenia associated with cancer chemotherapy","volume":"29","author":"Kuter","year":"2015","journal-title":"Oncology."},{"key":"B55","doi-asserted-by":"publisher","first-page":"100018","DOI":"10.1016\/j.bvth.2024.100018","article-title":"Structural basis of MPL activation by thrombopoietin","volume":"1","author":"Mafi","year":"2024","journal-title":"Blood Vessel Thromb Hemost."},{"key":"B56","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1097\/MOH.0000000000000170","article-title":"Novel mechanisms of platelet clearance and thrombopoietin regulation","volume":"22","author":"Grozovsky","year":"2015","journal-title":"Curr Opin Hematol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1600-0609.2008.01198.x","article-title":"AKR-501 (YM477) a novel orally-active thrombopoietin receptor agonist","volume":"82","author":"Fukushima-Shintani","year":"2009","journal-title":"Eur J Haematol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1080\/09537104.2021.1925102","article-title":"The thrombopoietin receptor: revisiting the master regulator of platelet production","volume":"32","author":"Hitchcock","year":"2021","journal-title":"Platelets."},{"key":"B59","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1016\/j.cell.2023.07.037","article-title":"Structure of the thrombopoietin-MPL receptor complex is a blueprint for biasing hematopoiesis","volume":"186","author":"Tsutsumi","year":"2023","journal-title":"Cell"},{"key":"B60","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.bbrc.2015.10.116","article-title":"C-Mannosylation of thrombopoietin receptor (c-Mpl) regulates thrombopoietin-dependent JAK-STAT signaling","volume":"468","author":"Sasazawa","year":"2015","journal-title":"Biochem Biophys Res Commun."},{"key":"B61","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1126\/science.aaw3242","article-title":"Mechanism of homodimeric cytokine receptor activation and dysregulation by oncogenic mutations","volume":"367","author":"Wilmes","year":"2020","journal-title":"Science."},{"key":"B62","doi-asserted-by":"publisher","first-page":"4398","DOI":"10.1038\/emboj.2011.315","article-title":"Orientation-specific signalling by thrombopoietin receptor dimers","volume":"30","author":"Staerk","year":"2011","journal-title":"EMBO J."},{"key":"B63","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1126\/science.abn8933","article-title":"Structure of a Janus kinase cytokine receptor complex reveals the basis for dimeric activation","volume":"376","author":"Glassman","year":"2022","journal-title":"Science."},{"key":"B64","doi-asserted-by":"publisher","first-page":"112201","DOI":"10.1016\/j.celrep.2023.112201","article-title":"Structural basis of Janus kinase trans-activation","volume":"42","author":"Caveney","year":"2023","journal-title":"Cell Rep."},{"key":"B65","doi-asserted-by":"publisher","first-page":"9041","DOI":"10.1021\/jp902377q","article-title":"The molecular origin of like-charge arginine-arginine pairing in water","volume":"113","author":"Vondr\u00e1sek","year":"2009","journal-title":"J Phys Chem B."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1007\/s40265-021-01613-y","article-title":"Avatrombopag: a review in thrombocytopenia","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs."},{"key":"B67","doi-asserted-by":"publisher","first-page":"20406207231152746","DOI":"10.1177\/20406207231152746","article-title":"Application and investigation of thrombopoiesis-stimulating agents in the treatment of thrombocytopenia","volume":"14","author":"Huang","year":"2023","journal-title":"Ther Adv Hematol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1182\/blood-2014-03-559815","article-title":"JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation","volume":"124","author":"Besancenot","year":"2014","journal-title":"Blood."},{"key":"B69","doi-asserted-by":"publisher","first-page":"13480","DOI":"10.1074\/jbc.274.19.13480","article-title":"Thrombopoietin signal transduction requires functional JAK2, not TYK2","volume":"274","author":"Drachman","year":"1999","journal-title":"J Biol Chem."},{"key":"B70","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12964-020-00626-6","article-title":"Orchestration of signaling by structural disorder in class 1 cytokine receptors","volume":"18","author":"Seiffert","year":"2020","journal-title":"Cell Commun Signal."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1038\/s41375-024-02219-5","article-title":"Differential in vivo roles of Mpl cytoplasmic tyrosine residues in murine hematopoiesis and myeloproliferative disease","volume":"38","author":"Behrens","year":"2024","journal-title":"Leukemia."},{"key":"B72","doi-asserted-by":"publisher","first-page":"38930","DOI":"10.1074\/jbc.M607524200","article-title":"The membrane-proximal region of the thrombopoietin receptor confers its high surface expression by JAK2-dependent and -independent mechanisms","volume":"281","author":"Tong","year":"2006","journal-title":"J Biol Chem."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.3324\/haematol.2016.146746","article-title":"Revealing eltrombopag's promotion of human megakaryopoiesis through AKT\/ERK-dependent pathway activation","volume":"101","author":"Di Buduo","year":"2016","journal-title":"Haematologica."},{"key":"B74","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41573-022-00557-6","article-title":"Emerging principles of cytokine pharmacology and therapeutics","volume":"22","author":"Saxton","year":"2023","journal-title":"Nat Rev Drug Discov."},{"key":"B75","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s12185-013-1382-0","article-title":"The biology of thrombopoietin and thrombopoietin receptor agonists","volume":"98","author":"Kuter","year":"2013","journal-title":"Int J Hematol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"4607","DOI":"10.1182\/blood-2006-10-019315","article-title":"New thrombopoietic growth factors","volume":"109","author":"Kuter","year":"2007","journal-title":"Blood."},{"key":"B77","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1074\/jbc.M115.696534","article-title":"His499 regulates dimerization and prevents oncogenic activation by asparagine mutations of the human thrombopoietin receptor","volume":"291","author":"Leroy","year":"2016","journal-title":"J Biol Chem."},{"key":"B78","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/ajh.24935","article-title":"Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: a retrospective collaborative survey from Italian hematology centers","volume":"93","author":"Cantoni","year":"2018","journal-title":"Am J Hematol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1182\/blood.V100.10.3457","article-title":"Recombinant human thrombopoietin: basic biology and evaluation of clinical studies","volume":"100","author":"Kuter","year":"2002","journal-title":"Blood."},{"key":"B80","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3760\/cma.j.issn.0253-2727.2020.08.001","volume":"41","year":"2020","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B81","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.clpt.2004.08.010","article-title":"Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand","volume":"76","author":"Wang","year":"2004","journal-title":"Clin Pharmacol Ther."},{"key":"B82","doi-asserted-by":"publisher","first-page":"3730","DOI":"10.1021\/jm010283l","article-title":"Hydrazinonaphthalene and azonaphthalene thrombopoietin mimics are nonpeptidyl promoters of megakaryocytopoiesis","volume":"44","author":"Duffy","year":"2001","journal-title":"J Med Chem."},{"key":"B83","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1080\/1744666X.2019.1587294","article-title":"Avatrombopag for the treatment of immune thrombocytopenia","volume":"15","author":"D\u0142ugosz-Danecka","year":"2019","journal-title":"Expert Rev Clin Immunol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1007\/s40265-021-01575-1","article-title":"Hetrombopag: first approval","volume":"81","author":"Syed","year":"2021","journal-title":"Drugs."},{"key":"B85","doi-asserted-by":"publisher","first-page":"e81521","DOI":"10.7554\/eLife.81521","article-title":"Constitutive activation and oncogenicity are mediated by loss of helical structure at the cytosolic boundary of thrombopoietin receptor mutant dimers","volume":"12","author":"Defour","year":"2023","journal-title":"Elife"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1056\/NEJMoa054626","article-title":"AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP","volume":"355","author":"Bussel","year":"2006","journal-title":"N Engl J Med."},{"key":"B87","doi-asserted-by":"publisher","first-page":"100909","DOI":"10.1016\/j.blre.2021.100909","article-title":"The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag","volume":"53","author":"Kuter","year":"2022","journal-title":"Blood Rev."},{"key":"B88","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/bcpt.12815","article-title":"Safety, Pharmacokinetics and Pharmacodynamics of hetrombopag olamine, a novel TPO-R agonist, in healthy individuals","volume":"121","author":"Zheng","year":"2017","journal-title":"Basic Clin Pharmacol Toxicol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1182\/blood.2022018665","article-title":"Prolonged response after TPO-RA discontinuation in primary ITP: results of a prospective multicenter study","volume":"141","author":"Guillet","year":"2023","journal-title":"Blood."},{"key":"B90","doi-asserted-by":"publisher","first-page":"5723","DOI":"10.1182\/blood-2010-11-321398","article-title":"Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia","volume":"117","author":"Barsam","year":"2011","journal-title":"Blood."},{"key":"B91","doi-asserted-by":"publisher","first-page":"881","DOI":"10.3324\/haematol.2012.074633","article-title":"A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia","volume":"98","author":"Khellaf","year":"2013","journal-title":"Haematologica."},{"key":"B92","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.exphem.2004.09.006","article-title":"Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist","volume":"33","author":"Erickson-Miller","year":"2005","journal-title":"Exp Hematol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/bjh.18081","article-title":"Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: a multicentre US study","volume":"197","author":"Al-Samkari","year":"2022","journal-title":"Br J Haematol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"100134","DOI":"10.1016\/j.rpth.2023.100134","article-title":"Durability of platelet response after switching to avatrombopag from eltrombopag or romiplostim in immune thrombocytopenia","volume":"7","author":"Al-Samkari","year":"2023","journal-title":"Res Pract Thromb Haemost."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.3324\/haematol.2016.153668","article-title":"Eltrombopag, a potent stimulator of megakaryopoiesis","volume":"101","author":"Raslova","year":"2016","journal-title":"Haematologica."},{"key":"B96","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.scr.2012.05.001","article-title":"Eltrombopag, a thrombopoietin receptor agonist, enhances human umbilical cord blood hematopoietic stem\/primitive progenitor cell expansion and promotes multi-lineage hematopoiesis","volume":"9","author":"Sun","year":"2012","journal-title":"Stem Cell Res."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.3324\/haematol.2018.212845","article-title":"Thrombopoietin receptor agonists: ten years later","volume":"104","author":"Ghanima","year":"2019","journal-title":"Haematologica."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1260487","DOI":"10.3389\/fcvm.2023.1260487","article-title":"Thrombopoietin-receptor agonists for adult patients with immune thrombocytopenia: a narrative review and an approach for managing patients fasting intermittently","volume":"10","author":"Yassin","year":"2023","journal-title":"Front Cardiovasc Med."},{"key":"B99","doi-asserted-by":"publisher","first-page":"102342","DOI":"10.1016\/j.rpth.2024.102342","article-title":"Thrombosis in patients with immune thrombocytopenia: incidence, risk, and clinical outcomes","volume":"8","author":"Goncalves","year":"2024","journal-title":"Res Pract Thromb Haemost."},{"key":"B100","doi-asserted-by":"publisher","first-page":"e70134","DOI":"10.1002\/jha2.70134","article-title":"Appropriate management of thrombotic risk in patients with primary immune thrombocytopenia in the UK: a modified delphi consensus","volume":"6","author":"Bradbury","year":"2025","journal-title":"EJHaem."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1111\/bjh.20100","article-title":"The \u2018Stop TPO-RA in ITP Patients' study: clinical and immune modulatory effects of romiplostim tapering","volume":"206","author":"Nelson","year":"2025","journal-title":"Br J Haematol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1007\/s00277-024-05826-5","article-title":"Switching from eltrombopag to hetrombopag in patients with primary immune thrombocytopenia: a post-hoc analysis of a multicenter, randomized phase III trial","volume":"103","author":"Mei","year":"2024","journal-title":"Ann Hematol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1749-6632.2011.05975.x","article-title":"The development of romiplostim for patients with immune thrombocytopenia","volume":"1222","author":"Molineux","year":"2011","journal-title":"Ann N Y Acad Sci."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1798504\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T04:23:52Z","timestamp":1780892632000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1798504\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":103,"alternative-id":["10.3389\/fmed.2026.1798504"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1798504","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"article-number":"1798504"}}